B
Bull
Bull · 25%CMMB
$1.23
情境價格
$2.710
-0.010 (-0.37%)收盤時
Loading chart…
- High
- 2.880
- Open
- 2.730
- VWAP
- 2.73
- Vol
- 105.16K
- Mkt Cap
- 13.81M
- Low
- 2.610
- Amount
- 287.44K
- EV/EBITDA, TTM
- 0.00
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
AI analysis of Chemomab Therapeutics Ltd (CMMB)
buyChemomab Therapeutics Ltd (CMMB) is a good buy right now due to its recent price increase of 25.46% over the last 5 days and a strong RSI of 94.74, suggesting momentum. The company is also preparing for a Phase 3 trial for its lead drug candidate, which could significantly enhance its market position. However, the main risk is its negative net income, which was -2,165,000 USD in Q2 2026, indicating ongoing financial losses.
估值指標
The current forward P/E ratio for Chemomab Therapeutics Ltd (CMMB) is 12.94, compared to its 5-year average forward P/E of -19.51.
Alphio AI Price Scenarios for CMMB
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件時間軸
資訊
8.508-19NewsfilterChemomab and Scipher Merger Progressing
7.507-10NASDAQ.COMKey Developments in Biotech Sector This Week
8.507-08seekingalphaChemomab and Scipher Enter Definitive Merger Agreement
- 8.507-08Newsfilter
Chemomab and Scipher Merge to Advance RA Drug Development
2.007-03NASDAQ.COMBiotech Companies See Significant Stock Gains
CMMB FAQ — answered by Alphio AI
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Chemomab Therapeutics Ltd (CMMB) is a good buy right now due to its recent price increase of 25.46% over the last 5 days and a strong RSI of 94.74, suggesting momentum. The company is also preparing for a Phase 3 trial for its lead drug candidate, which could significantly enhance its market position. However, the main risk is its negative net income, which was -2,165,000 USD in Q2 2026, indicating ongoing financial losses.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。